Journals / Türk Patoloji Dergisi / 2019 / Cilt: 35 - Sayı: 2

Two-Year Results of Community-Based Screening Program for Human Papilloma Virus DNA in Çorum Province

Pages
102–106
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This shows that despite the screening, the desired therapeutic effect could not be achieved.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The Turkish Ministry of Health started a community-based screening program using Human Papilloma Virus (HPV) DNA in 2014.In our study, we aimed to investigate the results of this survey in Çorum province between the years of 2016-17 to determine the shortcomingsand deficiencies in practice.Material and Method: All of the women between the ages of 30 and 65 years who had undergone High risk HPV DNA screening in Çorumprovince between 2016 and 2017 were included in the study.
📊
Key Findings & Data:High risk HPV types were divided into three categories as type 16, 18 and others.
💡
Conclusion & Impact:This shows that despite the screening, the desired therapeutic effect could not be achieved.
🔬Design:Survey & Empirical Study
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The Turkish Ministry of Health started a community-based screening program using Human Papilloma Virus (HPV) DNA in 2014.In our study, we aimed to investigate the results of this survey in Çorum province between the years of 2016-17 to determine the shortcomingsand deficiencies in practice.Material and Method: All of the women between the ages of 30 and 65 years who had undergone High risk HPV DNA screening in Çorumprovince between 2016 and 2017 were included in the study. High risk HPV types were divided into three categories as type 16, 18 and others. Thetarget group of patients to be screened were compared with the numbers reached in the survey. After colposcopic biopsy, the clinicopathologicalcorrelation of the patients who underwent colposcopic biopsy was determined via pathology reports.Results: HPV DNA was detected in 817 women (3.5%). HPV types 16, 18 and others were found to be positive in 216, 32 and 569 individuals,respectively. Cervical biopsy was performed with colposcopy in 212 (26%) women. As the result of colposcopy, LSIL and HSIL were detected in63 and 56 patients, respectively. 34.5% of patients with the diagnosis of any kind of dysplasia received treatments.Conclusion: It was determined that 44% of HPV DNA-positive patients were not subjected to the appropriate processes according to the nationalguidelines. This shows that despite the screening, the desired therapeutic effect could not be achieved.

🔖

Cite This Article

GÜNEY, G., TURGAL, E., BAŞ, Y., ARSLAN, E. (2022). Two-Year Results of Community-Based Screening Program for Human Papilloma Virus DNA in Çorum Province. Türk Patoloji Dergisi, Cilt: 35 - Sayı: 2, 102–106. https://ajindex.com/articles/640434

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917
  2. Wardak S. Human Papillomavirus (HPV) and cervical cancer. Med Dosw Mikrobiol. 2016;68:73-84
  3. Zhang L, Bi Q, Deng H, Xu J, Chen J, Zhang M, Mu X. Human papillomavirus infections among women with cervical lesions and cervical cancer in Eastern China: Genotype-specific prevalence and attribution. BMC Infect Dis. 2017;17:107
  4. Sasaki Y, Iwanari O, Arakawa I, Moriya T, Mikami Y, Iihara K, Konno R. Cervical cancer screening with human papillomavirus DNA and cytology in Japan. Int J Gynecol Cancer. 2017;27: 523-9
  5. Fernandez AF, Rosales C, Lopez-Nieva P, Graña O, Ballestar E, Ropero S, Espada J, Melo SA, Lujambio A, Fraga MF,Pino I, Javierre B, Carmona FJ, Acquadro F, Steenbergen RD, Snijders PJ, Meijer CJ, Pineau P, Dejean A, Lloveras B, Capella G, Quer J, Buti M, Esteban JI, Allende H, Rodriguez-Frias F, Castellsague X, Minarovits J, Ponce J, Capello D, Gaidano G, Cigudosa JC, Gomez-Lopez G, Pisano DG, Valencia A, Piris MA, Bosch FX, Cahir-McFarland E, Kieff E, Esteller M. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 2009;19:438-51
  6. Ghosh S, Seth, Paul J, Rahman R, Chattopathyay S, Bhadra D. Evaluation of Pap smear, high risk HPV DNA testing in detection of cervical neoplasia with colposcopy guided or conventional biopsy as gold standard. Int J Healthcare Biomed Res. 2014;2: 192-7
  7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9
  8. Harper DM, DeMars LR. HPV vaccines ‐ a review of the first decade. Gynecol Oncol. 2017;146:196-204
  9. Catarino R, Petignat P, Dongui G, Vassilakos P. Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol. 2015;6: 281-90
  10. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86
  11. Açikgöz A, Ergör G. Cervical cancer risk levels in Turkey and compliance to the national cervical cancer screening standard. Asian Pac J Cancer Prev. 2011;12:923-7
  12. Sevil S, Kevser O, Aleattin U, Özlem D. The frequency of hav